Ascletis Pharma Inc
HKEX:1672

Watchlist Manager
Ascletis Pharma Inc Logo
Ascletis Pharma Inc
HKEX:1672
Watchlist
Price: 1.6 HKD -5.33% Market Closed
Market Cap: 1.6B HKD
Have any thoughts about
Ascletis Pharma Inc?
Write Note

Ascletis Pharma Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ascletis Pharma Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Ascletis Pharma Inc
HKEX:1672
Income from Continuing Operations
-ÂĄ144.7m
CAGR 3-Years
12%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Income from Continuing Operations
-ÂĄ6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Income from Continuing Operations
ÂĄ1.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Income from Continuing Operations
ÂĄ1.2B
CAGR 3-Years
22%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Income from Continuing Operations
ÂĄ1.8B
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Income from Continuing Operations
ÂĄ3.7B
CAGR 3-Years
-26%
CAGR 5-Years
12%
CAGR 10-Years
39%
No Stocks Found

Ascletis Pharma Inc
Glance View

Market Cap
1.6B HKD
Industry
Biotechnology

Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Intrinsic Value
0.7 HKD
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Ascletis Pharma Inc's Income from Continuing Operations?
Income from Continuing Operations
-144.7m CNY

Based on the financial report for Dec 31, 2023, Ascletis Pharma Inc's Income from Continuing Operations amounts to -144.7m CNY.

What is Ascletis Pharma Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-49%

Over the last year, the Income from Continuing Operations growth was 54%. The average annual Income from Continuing Operations growth rates for Ascletis Pharma Inc have been 12% over the past three years , -49% over the past five years .

Back to Top